» Articles » PMID: 37676305

Functional Characterization of CpADF, an Actin Depolymerizing Factor Protein in Cryptosporidium Parvum

Overview
Journal Parasitol Res
Specialty Parasitology
Date 2023 Sep 7
PMID 37676305
Authors
Affiliations
Soon will be listed here.
Abstract

Cryptosporidium is a highly pathogenic water and food-borne zoonotic parasitic protozoan that causes severe diarrhea in humans and animals. Apicomplexan parasites invade host cells via a unique motility process called gliding, which relies on the parasite's microfilaments. Actin depolymerizing factor (ADF) is a fibrous-actin (F-actin) and globular actin (G-actin) binding protein essential for regulating the turnover of microfilaments. However, the role of ADF in Cryptosporidium parvum (C. parvum) remains unknown. In this study, we preliminarily characterized the biological functions of ADF in C. parvum (CpADF). The CpADF was a 135-aa protein encoded by cgd5_2800 gene containing an ADF-H domain. The expression of cgd5_2800 gene peaked at 12 h post-infection, and the CpADF was located in the cytoplasm of oocysts, middle region of sporozoites, and cytoplasm of merozoites. Neutralization efficiency of anti-CpADF serum was approximately 41.30%. Actin sedimentation assay revealed that CpADF depolymerized but did not undergo cosedimentation with F-actin and its ability of F-actin depolymerization was pH independent. These results provide a basis for further investigation of the roles of CpADF in the invasion of C. parvum.

References
1.
Abrahamsen M . Cryptosporidium parvum genome project. Comp Funct Genomics. 2008; 2(1):19-21. PMC: 2447187. DOI: 10.1002/cfg.67. View

2.
Baroni L, Abreu-Filho P, Pereira L, Nagl M, Yatsuda A . Recombinant actin-depolymerizing factor of the apicomplexan (NcADF) is susceptible to oxidation. Front Cell Infect Microbiol. 2023; 12:952720. PMC: 9806845. DOI: 10.3389/fcimb.2022.952720. View

3.
Cai X, Woods K, Upton S, Zhu G . Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother. 2005; 49(11):4437-42. PMC: 1280145. DOI: 10.1128/AAC.49.11.4437-4442.2005. View

4.
Cevallos A, Bhat N, Verdon R, Hamer D, Stein B, Tzipori S . Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody. Infect Immun. 2000; 68(9):5167-75. PMC: 101770. DOI: 10.1128/IAI.68.9.5167-5175.2000. View

5.
Checkley W, White Jr A, Jaganath D, Arrowood M, Chalmers R, Chen X . A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2014; 15(1):85-94. PMC: 4401121. DOI: 10.1016/S1473-3099(14)70772-8. View